SEARCH

SEARCH BY CITATION

References

  • 1
    Centers for Disease Control and Prevention. Cigarette smoking among adults-United States, 2002. Morb Mortal Wkly Rep 2004; 53: 427431.
  • 2
    Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost, and economic costs—United States, 1995-1999. Morb Mortal Wkly Rep 2002; 51: 300303.
  • 3
    Mokdad AH, Mark JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 2004; 291: 12381245.
  • 4
    Windsor R, Oncken C, Henningfield J, et al. Behavioral and pharmacological treatment methods for pregnant smokers: issues for clinical practice. J Am Med Womens Assoc 2000; 55: 304310.
  • 5
    US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2004.
  • 6
    Gritz ER, Vidrine DJ, Lazev AB. Smoking cessation in cancer patients: Never too late to quit, in GivenCW, GivenB, ChampionVL, et al. (eds). Evidence-based cancer care and prevention. New York: Springer Publishing Company; 2003: 107140.
  • 7
    Wald NJ, Watt HC. Prospective study of effect of switching from cigarettes to pipes or cigars on mortality from three smoking related diseases. BMJ 1997; 314: 18601863.
  • 8
    Baker F, Ainsworth SR, Dye JT, et al. Health risks associated with cigar smoking. JAMA 2000; 284: 735740.
  • 9
    Connolly GN, Winn DM, Hecht SS, et al. The reemergence of smokeless tobacco. N Engl J Med 1986; 314: 10201027.
  • 10
    Hatsukami DK, Severson HH. Oral spit tobacco: addiction, prevention and treatment. Nicotine Tob Res 1999; 1: 2144.
  • 11
    Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2000.
  • 12
    US Department of Health and Human Services. Management of Nicotine Addiction. Reducing Tobacco Use: A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2000.
  • 13
    World Health Organization. Policy Recommendations for Smoking Cessation and Treatment of Tobacco Dependence. Geneva, Switzerland: World Health Organization; 2003.
  • 14
    World Bank. Curbing the Epidemic: Governments and the Economics of Tobacco Control. Washington, DC: World Bank; 1999.
  • 15
    Benowitz NL, Porchet H, Sheiner L, Jacob P III. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 1988; 44: 2328.
  • 16
    Benowitz NL, Henningfield JE. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med 1994; 331: 123125.
  • 17
    US Department of Health and Human Services. The Health Consequences of Smoking: Nicotine Addiction, A Report of the Surgeon General. Washington, DC: US Government Printing Office; 1988.
  • 18
    Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86: 11191127.
  • 19
    American Psychiatric Association. Diagnostic and statistical manual—IVTR. Washington, DC: American Psychiatric Association; 2000.
  • 20
    Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995; 333: 11961203.
  • 21
    American Psychiatric Association. Practice guideline for the treatment of patients with nicotine dependence. Am J Psychiatry 1996; 153(Suppl 10)): 131.
  • 22
    Benowitz NL. Nicotine replacement therapy. What has been accomplished-can we do better? Drugs 1993; 45: 157170.
  • 23
    Butschky MF, Bailey D, Henningfield JE, Pickworth WB. Smoking without nicotine delivery decreases withdrawal in 12-hour abstinent smokers. Pharmacol Biochem Behav 1995; 50: 9196.
  • 24
    Finnegan JK, Larson PS, Haag HB. The role of nicotine in the cigarette habit. Science 1945; 102: 9496.
  • 25
    Rose JE, Behm FM, Westman EC, et al. Pharmacologic and sensorimotor components of satiation in cigarette smoking. Pharmacol Biochem Behav 2003; 76: 243250.
  • 26
    Brauer LH, Behm FM, Lane JD, et al. Individual differences in smoking reward from de-nicotinized cigarettes. Nicotine Tob Res 2001; 3: 101109.
  • 27
    Snyder FR, Henningfield JE. Effects of nicotine administration following 12h of tobacco deprivation: assessment on computerized performance tasks. Psychopharmacology 1989; 97: 1722.
  • 28
    Pickworth WB, Fant RV, Butschky MF, Henningfield JE. Effects of transdermal nicotine delivery on measures of acute nicotine withdrawal. J Pharmacol Exp Ther 1996; 279: 450456.
  • 29
    Shiffman S, Paty JA, Rohay JM, et al. The efficacy of computer-tailored smoking cessation material as a supplement to nicotine patch therapy. Drug Alcohol Depend 2001; 64: 3546.
  • 30
    Sweeney CT, Fant RV, Fagerstrom KO, et al. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs 2001; 15: 453467.
  • 31
    Fagerstrom KO. Combined use of nicotine replacement products. Health Values 1994; 18: 1520.
  • 32
    Jacox A, Carr DB, Payne R, et al. Management of Cancer Pain. Clinical Practice Guideline No. 9. AHCPR Publication No. 94-0592. Rockville, MD: Agency for Health Care Policy and Research, US Department of Health and Human Services, Public Health Service; 2004.
  • 33
    Benowitz NL. Clinical pharmacology of transdermal nicotine. Eur J Pharm Biopharm 1995; 41: 168174.
  • 34
    Gorsline J. Nicotine pharmacokinetics of four nicotine transdermal systems. Health Values 1993; 17: 2024.
  • 35
    Fant RV, Henningfield JE, Shiffman S, et al. A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav 2000; 67: 479482.
  • 36
    Shiffman S, Elash CA, Paton SM, et al. Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving. Addiction 2000; 95: 11851195.
  • 37
    Hajek P, West R, Foulds J, et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999; 159: 20332038.
  • 38
    Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995; 333: 11961203.
  • 39
    Tiffany ST, Cox LS, Elash CA. Effects of transdermal nicotine patches on abstinence-induced and cue- elicited craving in cigarette smokers. J Consult Clin Psychol 2000; 68: 233240.
  • 40
    Shiffman S, Engberg JB, Paty JA, et al. A day at a time: predicting smoking lapse from daily urge. J Abnorm Psychol 1997; 106: 104116.
  • 41
    Shiffman S, Gnys M, Richards TJ, et al. Temptations to smoke after quitting: a comparison of lapsers and maintainers. Health Psychol 1996; 15: 455461.
  • 42
    Shiffman S, Rolf CN, Hellebusch SJ, et al. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction 2002; 97: 505516.
  • 43
    Shiffman S, Gitchell J, Pinney JM, et al. Public health benefit of over-the-counter nicotine medications. Tob Control 1997; 6: 306310.
  • 44
    Benowitz NL, Jacob P, III, Savanapridi C. Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin Pharmacol Ther 1987; 41: 467473.
  • 45
    Herrera N, Franco R, Herrera L, et al. O. Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. Chest 1995; 108: 447451.
  • 46
    Tonnesen P, Fryd V, Hansen M, et al. Two and four mg nicotine chewing gum and group counselling in smoking cessation: an open, randomized, controlled trial with a 22 month follow-up. Addict Behav 1988; 13: 1727.
  • 47
    Russell MAH, Merriman R, Stapleton J, Taylor W. Effect of nicotine chewing gum as an adjunct to general practitioner's advice against smoking. BMJ 1983; 287: 17821785.
  • 48
    Henningfield JE, Stapleton JM, Benowitz NL, et al. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 1993; 33: 2329.
  • 49
    Henningfield JE, Radzius A, Cooper TM, Clayton RR. Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum. JAMA 1990; 264: 15601564.
  • 50
    Shiffman S, Shadel WG, Niaura R, et al. Efficacy of acute administration of nicotine gum in relief of cue- provoked cigarette craving. Psychopharmacology 2003; 166: 343350.
  • 51
    Cohen LM, Collins FL, Brt DM. The effect of chewing gum on tobacco withdrawal. Addict Behav 1997; 22: 769773.
  • 52
    Shiffman S, Dresler CM, Hajek P, et al. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002; 162: 12671276.
  • 53
    Choi JH, Dresler CM, Norton MR, Strahs KR. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 2003; 5: 635644.
  • 54
    Molander L, Lunell E, Andersson SB, Kuylenstierna F. Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler. Clin Pharmacol Ther 1996; 59: 394400.
  • 55
    Bergstrom M, Nordberg A, Lunell E, et al. Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography. Clin Pharmacol Ther 1995; 57: 309317.
  • 56
    Lunell E, Molander L, Andersson SB. Temperature dependency of the release and bioavailability of nicotine from a nicotine vapour inhaler; in vitro/ in vivo correlation. Eur J Clin Pharmacol 1997; 52: 495500.
  • 57
    Schneider NG, Lunell E, Olmstead RE, Fagerstrom KO. Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin Pharmacokinet 1996; 31: 6580.
  • 58
    Hurt RD, Offord KP, Croghan IT, et al. Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms. Psychopharmacology 1998; 140: 98104.
  • 59
    Molander L, Lunell E. Pharmacokinetic investigation of a nicotine sublingual tablet. Eur J Clin Pharmacol 2001; 56: 813819.
  • 60
    Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials. Transdermal Nicotine Study Group. JAMA 1991; 266: 31333138.
  • 61
    Zevin S, Jacob P III, Benowitz NL. Dose-related cardiovascular and endocrine effects of transdermal nicotine. Clin Pharmacol Ther 1998; 64: 8795.
  • 62
    Tonnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J 1999; 13: 238246.
  • 63
    Jorenby DE, Smith SS, Fiore MC, et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995; 274: 13471352.
  • 64
    Hughes, Jr, Lesmes GR, Hatsukami DK, et al. Are higher doses of nicotine replacement more effective for smoking cessation. Nicotine Tob Res 1999; 1: 169174.
  • 65
    Shiffman S, Paty JA, Gnys M, et al. First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol 1996; 64: 366379.
  • 66
    Cherukuri SR, Pinney JM, Henningfield JE, et al. Medicated chewing gum delivery system for nicotine. Patent No. 6,344,222. Bethesda, MD: JSR, LLC; February 5, 2002.
  • 67
    Niaura R, Sayette MA, Shiffman S, et al. Comparative efficacy of rapid-release nicotine gum vs. Nicorette in relieving smoking cue-provoked craving. Presented at: Annual Meeting of the Society for Research on Nicotine and Tobacco; February 19–22, 2003; New Orleans, LA.
  • 68
    Henningfield JE, Stapleton JM, Benowitz NL, et al. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 1993; 33: 2329.
  • 69
    Fagerstrom KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology 1993; 111: 271277.
  • 70
    Kornitzer M, Boutsen M, Dramaix M, et al. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med 1995; 24: 4147.
  • 71
    Puska P, Korhonen H, Vartiainen E, et al. Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tob Control 1995; 4: 231235.
  • 72
    Blondal T, Gudmundsson LJ, Olafsdottir I, et al. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ 1999; 318: 285289.
  • 73
    Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685691.
  • 74
    Shiffman S, Gitchell JG, Warner KE, et al. Tobacco harm reduction: conceptual structure and nomenclature for analysis and research. Nicotine Tob Res 2002; 4(Suppl 2)): S113S129.
  • 75
    Hall SM, Humfleet GL, Reus VI, et al. Extended nortriptyline and psychological treatment for cigarette smoking. Am J Psychiatry 2004; 161: 21002107.
  • 76
    Hurt RD, Wolter TD, Rigotti N, et al. Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome. Addict Behav 2002; 27: 493507.
  • 77
    Baer JS, Kamarck T, Lichtenstein E, Ransom CC, Jr. Prediction of smoking relapse: analyses of temptations and transgressions after initial cessation. J Consult Clin Psychol 1989; 57: 623627.
  • 78
    Garvey AJ, Bliss RE, Hitchcock JL, et al. Predictors of smoking relapse among self-quitters: a report from the Normative Aging Study. Addict Behav 1992; 17: 367377.
  • 79
    Kenford SL, Fiore MC, Jorenby DE, et al. Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA 1994; 271: 589594.
  • 80
    Shiffman S, Scharf D. Milestones in smoking cessation: a process analysis. Presented at: Eighth Annual Meeting of the Society for Research on Nicotine and Tobacco; February 20–23, 2002; Savannah, GA.
  • 81
    Balfour DJ, Fagerstrom KO. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 1996; 72: 5181.
  • 82
    Hurt R. Clinical Implications of Long-Term Nicotine Use, in FerrenceR, SladeJ, RoomR, PopeM (eds). Nicotine and Public Health. Washington, DC: American Public Health Association; 2000: 389409.
  • 83
    Institute of Medicine. Executive Summary, in StrattonK, ShettyP, WallaceR, BondurantS (eds). Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. Washington DC: National Academy Press; 2001: 114.
  • 84
    Shiffman S, Gitchell J, Warner KE, et al. Tobacco harm reduction: conceptual structure and nomenclature for analysis and research. Nicotine Tob Res 2002; 4(Suppl 2)): S113S129.
  • 85
    Benowitz NL. Compensatory Smoking of Low-Yield Cigarettes, in National Cancer Institute. Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2001: 3963.
  • 86
    Hughes, Jr. Reduced smoking: an introduction and review of the evidence. Addiction 2000; 95(Suppl 1)): S3S7.
  • 87
    Fagerstrom KO, Hughes, Jr. Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: a review. Nicotine Tob Res 2002; 4(Suppl 2)): S73S79.
  • 88
    Lerman C, Niaura R, Collins BN, et al. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol Addict Behav 2004; 18: 362366.
  • 89
    Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) 2003; 168: 347358.
  • 90
    Bruijnzeel AW, Markou A. Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. SYNAPSE 2003; 50: 2028.
  • 91
    Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology 1989; 2: 273279.
  • 92
    Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology 1992; 7: 714.
  • 93
    Scharf D, Shiffman S. Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR. Addiction 2004; 99: 14621469.
  • 94
    Shiffman S, Johnston JA, Khayrallah M, et al. The effect of bupropion on nicotine crav-ing and withdrawal. Psychopharmacology 2000; 148: 3340.
  • 95
    Henningfield JE, Fant RV, Gopalan L. Non-nicotine medications for smoking cessation. J Respir Dis 1998; 19: S33S42.
  • 96
    Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004; 4: CD000031.
  • 97
    Ferry LH. Non-nicotine pharmacotherapy for smoking cessation. Prim Care 1999; 26: 653669.
  • 98
    Prochazka AV, Weaver MJ, Keller RT, et al. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998; 158: 20352039.
  • 99
    Hall SM, Reus VI, Munoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998; 55: 683689.
  • 100
    Prochazka AV, Kick S, Steinbrunn C, et al. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med 2004; 164: 22292233.
  • 101
    Edwards NB, Murphy JK, Downs AD, et al. Doxepin as an adjunct to smoking cessation: a double-blind pilot study. Am J Psychiatry 1989; 146: 373376.
  • 102
    Edwards NB, Simmons RC, Rosenthal TL, et al. Doxepin in the treatment of nicotine withdrawal. Psychomatics 1988; 29: 203206.
  • 103
    Murphy JK, Edwards NB, Downs AD, et al. Effects of doxepin on withdrawal symptoms in smoking cessation. Am J Psychiatry 1990; 147: 13531357.
  • 104
    Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 1988; 21: 253259.
  • 105
    Mayo-Smith MF. Management of alcohol intoxication and withdrawal, in GrahamAW, SchultzTK, WilfordBB (eds.). Principles of Addiction Medicine. 2nd ed. Chevy Chase, MD: American Society of Addiction Medicine; 1998: 431440.
  • 106
    Glassman AH, Stetner F, Walsh BT, et al. Heavy smokers, smoking cessation, and clonidine: results of a double-blind, randomized trial. JAMA 1988; 259: 28632866.
  • 107
    Black SC. Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drugs 2004; 5: 389394.
  • 108
    Cohen C, Perrault G, Voltz C, et al. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 2002; 13: 451463.
  • 109
    Anthenelli R. Smoking cessation in smokers motivated to quit. Presented at: American College of Cardiology Scientific Sessions; March 7–10, 2004; New Orleans, LA.
  • 110
    Klesges RC, Winders SE, Meyers AW, et al. How much weight gain occurs following smoking cessation? A comparison of weight gain using both continuous and point prevalence abstinence. J Consult Clin Psychol 1997; 65: 286291.
  • 111
    Klesges RC, Meyers AW, Klesges LM, La Vasque ME. Smoking, body weight, and their effects on smoking behavior: a comprehensive review of the literature. Psychol Bull 1989; 106: 204230.
  • 112
    Pfizer. Available at: http://www.pfizer.com/pfizer/download/news/2005ql_earnq&a.pdf. Accessed September 28, 2004.
  • 113
    Cerny T. Anti-nicotine vaccination:where are we? Recent Results Cancer Res 2005; 166: 167175.
  • 114
    de Granda Orive JI. When will the nicotine vaccine be ready? Arch Bronconeumol 2005; 41: 24.
  • 115
    Cornuz J, Klingler K, Mueller P, et al. A therapeutic vaccine for nicotine dependence: results of a phase I and a randomized phase II study. Presented at: American Society of Clinical Oncology; May 2005; Orlando, FL. Available at: http://www.asco.org/ac/1,1003,_12-002643-00_18-0034-00_19-0033424,00.asp. Accessed June 16, 2005.
  • 116
    Pentel PR, Malin DH, Ennifar S, et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000; 65: 191198.
  • 117
    de Villiers SH, Lindblom N, Kalayanov G, et al. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 2002; 69: 247253.
  • 118
    Lindblom N, de Villiers SH, Kalayanov G, et al. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 2002; 69: 254260.
  • 119
    Hasman A, Holm S. Nicotine conjugate vaccine:is there a right to a smoking future? J Med Ethics 2004; 30: 344345.
  • 120
    Royal College of Physicians. Nicotine Addiction In Brain: A Report of the Tobacco Advisory Group of the Royal College of Physicians. London, UK: Royal College of Physicians of London; 2000.
  • 121
    Lerman C, Patterson F, Berrettini W. Treating tobacco dependence: state of the science and new directions. J Clin Oncol 2005; 23: 311323.
  • 122
    Cummings KM, Hyland A. Impact of nicotine replacement therapy on smoking behavior. Annu Rev Public Health 2005; 26: 583599.
  • 123
    Nielsen K, Fiore MC. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation. Prev Med 2000; 30: 209216.
  • 124
    Henningfield JE. Tobacco dependence treatment: scientific challenges; public health opportunities. Tob Control 2000; 9(Suppl 1)): I3I10.
  • 125
    Warner KE, Mendez D, Smith DG. The financial implications of coverage of smoking cessation treatment by managed care organizations. Inquiry 2004; 41: 5769.